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ABSTRACT
p66Shc attenuates mitogenic, prosurvival and chemotactic signaling and 
promotes apoptosis in lymphocytes. Consistently, p66Shc deficiency contributes to 
the survival and trafficking abnormalities of chronic lymphocytic leukemia (CLL) B 
cells. The mechanism of p66shc silencing in CLL B cells is methylation-independent, at 
variance with other cancer cell types. Here we identify STAT4 as a novel transcriptional 
regulator of p66Shc in B cells. Chromatin immunoprecipitation and reporter gene 
assays showed that STAT4 binds to and activates the p66shc promoter. Silencing or 
overexpression of STAT4 resulted in a co-modulation of p66Shc. IL-12-dependent 
STAT4 activation caused a coordinate increase in STAT4 and p66Shc expression, 
which correlated with enhanced B cell apoptosis. Treatment with the STAT4 inhibitor 
lisofylline reverted partly this effect, suggesting that STAT4 phosphorylation is not 
essential for but enhances p66shc transcription. Additionally, we demonstrate that 
CLL B lymphocytes have a STAT4 expression defect which partly accounts for their 
p66Shc deficiency, as supported by reconstitution experiments. Finally, we show that 
p66Shc participates in a positive feedback loop to promote STAT4 expression. These 
results provide new insights into the mechanism of p66Shc expression in B cells and 
its defect in CLL, identifying the STAT4/IL-12 pathway as a potential therapeutic 
target in this neoplasia.
INTRODUCTION
p66Shc is a member of the Shc (Src homology 
2 domain containing) family of protein adaptors that 
negatively regulates proliferative and pro-survival 
signaling [1-6] and promotes moreover apoptosis by 
increasing intracellular oxidants [7]. As opposed to 
the ubiquitously expressed p52Shc and p46Shc, which 
are encoded by the same locus, p66Shc is expressed 
in a tissue-specific manner due to the presence of two 
alternative promoters in the ShcA locus regulating 
the transcripts encoding p52Shc/p46Shc and p66Shc, 
respectively [8]. The regulatory region of p66shc is 
characterized by the presence of a CpG-rich region that 
can be hyper-methylated, leading to promoter silencing 
[8, 9]. Although DNA modifications are responsible for 
p66shc silencing in epithelial as well as in T cells, the 
mechanism of p66Shc regulation in other cell types has yet 
not been elucidated. The absence of transcription factors 
specifically able to bind and activate the p66shc promoter 
may provide an alternative or additional mechanism, as 
exemplified by nuclear erythroid 2-related factor 2 (Nrf2), 
which binds to an antioxidant response element on the 
p66shc promoter [10, 11].
We have recently shown that neoplastic B cells from 
Chronic Lymphocytic Leukemia (CLL) patients exhibit 
a defect in p66shc expression, with the lowest levels 
displayed by patients with unfavorable prognosis [6]. 
Interestingly, although the presence of methylated CpG 
sites in the p66shc promoter may account in part for the 
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relatively low expression levels of p66Shc in healthy B 
cells, neither the overall methylation status of the CpG-
rich region nor the methylation of individual CpG sites 
differ between healthy and CLL B cells [6], indicating that 
a transcriptional rather than epigenetic mechanism may 
account for the p66Shc expression defect in neoplastic 
cells.
Here we show that STAT4 regulates p66Shc 
expression in B cells by interacting with several specific 
binding sites in the p66shc promoter. Of note, the p66Shc 
defect in CLL B cells correlates with impaired STAT4 
expression. Interestingly, we found that p66Shc is in 
turn able to promote the expression of several genes 
participating in the IL-12 pathway and regulated by 
STAT4, including STAT4 itself, and reconstitution of 
p66Shc in CLL B cells normalizes the levels of STAT4. 
The data highlight a new mechanism of transcriptional 
regulation of p66Shc in B cells mediated by STAT4 
binding to the p66shc promoter and provide evidence of 
a feedback regulatory loop whereby p66Shc modulates 
STAT4. They identify moreover STAT4 deficiency as a 
potential player in the response of CLL B cells with the 
tumor microenvironment.
RESULTS AND DISCUSSION
Gene expression profile analysis associates 
p66Shc to expression of IL-12 responsive genes 
in B cells
We have shown that p66Shc is able to modulate 
the expression of several genes critical to B-cell survival 
and homing through both its adaptor and pro-oxidant 
activities [6, 12]. To achieve insights into the processes 
regulated by p66Shc we used an unbiased approach 
involving a gene expression profile analysis on B cells 
stably transfected with a plasmid encoding p66Shc 
(MEC-p66) or the respective empty vector (MEC-Ctr). 
The MEC-1 cell line was used for these experiments as 
endogenous p66shc is completely silenced by promoter 
methylation, as supported by the fact that treatment with 
the demethylating agent 5-Aza-2’-deoxycytidine (AZA, 
decitabine) restored its expression (Supplementary Figure 
S1A) [13]. Two independent mRNA extractions were 
profiled for each sample using the Affymetrix HuGene 
2.0-st-v1 array. An ANOVA model to identify genes 
differentially expressed between the two groups was 
created and the transcripts with a fold-change higher than 
2 and a statistically significant p-value (P<0.05) were 
identified. A hierarchical clustering of the results is shown 
in Supplementary Figure S2.
Six genes, IL10, IL18RAP, IL1B, IL7R, IFNγ, and 
IFNGR1, were chosen for further validation based on their 
mRNA fold-changes and p-values (Table 1). Validation 
was carried out by qRT-PCR on three independent mRNA 
extractions from MEC-p66 and MEC-Ctr cells. The levels 
of IFNγ, IL1β and IL10 (Figure 1A), as well as of IFNγR1, 
IL18RAP and IL7R (Figure 1B), mRNA, were confirmed 
to be up-regulated in p66Shc-overexpressing cells 
compared to the empty vector transfectant. Consistent with 
the qRT-PCR data, IFN-γ, IL-1β and IL-10, whose mRNA 
levels showed the largest fold-changes, were up-regulated 
in MEC-p66 cells compared to control cells, as assessed 
by flow cytometry (Figure 1C).
Interestingly, the products of the six genes identified 
in the analysis participate in pathways driven by IL-12 
and its primary mediator, Signal Transducer and Activator 
of Transcription 4 (STAT4). The IL-12 pathway is 
essential for CD4+ T cell commitment to the Th1 subset 
[14, 15], where IL-12 promotes the STAT4-dependent 
expression of IFN-γ [16, 17]. The genes of the IL-12/
IFN-γ axis include IFNGR1, IL18RAP, IL10, IL1B and 
IL7R [18-21]. Since STAT4 expression and activation 
are crucial for the response to IL-12 [22], the levels of 
STAT4 were quantified in p66Shc overexpressing MEC-1 
cells. As shown in Figure 1D, the STAT4 transcript was 
significantly up-regulated in MEC-p66 cells. This gene 
had not been identified in the Affymetrix array analysis 
because the difference compared to the MEC-Ctr (1.72-
fold) was lower than the 2-fold threshold used.
STAT4 recognizes and binds to the p66shc 
regulatory region in B cells
At variance with other cell types [8, 9, 23-25], 
gene promoter modification have been ruled out as the 
primary mechanism of transcriptional regulation of 
p66shc in both normal and CLL B cells notwithstanding 
a partial methylation of the CpG sites [6], indicating 
that different mechanisms are operational in these cells, 
such as recruitment of chromatin-remodeling enzymes or 
availability of specific transcription factors.
To identify transcriptional regulators we performed 
an in silico analysis using the JASPAR software on the 
p66shc locus, focusing on a region of ~2 kb encompassing 
nucleotides −1830 to +71, +1 being the transcription start 
site (TSS). We identified 1668 putative binding sites for 
several transcription factors in the sequence analyzed, 
confirming previously reported binding sequences for 
factors such as SP1, NF-AT and GATA3 [8]. Interestingly, 
we identified several sites for members of the STAT 
family, suggesting that these proteins might participate in 
p66shc regulation. We focused on STAT4, as this is the 
main effector in the IL-12 pathway that we found altered 
in p66Shc-overexpressing cells.
Four putative binding sites for STAT4 were 
identified in the proximity of the p66shc TSS (Figure 2A, 
Supplementary Table S1). These sites are far from the 
CpG-rich region, suggesting that they may be accessible 
even when the CpG sites are partially methylated. 
Chromatin Immunoprecipitation (ChIP) assays were 
performed to assess whether STAT4 can bind to these 
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sites. For these experiments we used EBV-immortalized 
primary human B cells rather than MEC-1 cells because, 
as opposed to the latter, these cells express p66Shc 
(Supplementary Figure S1B), indicating that the p66shc 
promoter is accessible to transcription factors. Two sets of 
primers were designed to amplify the regions of interest, 
one spanning nucleotides −1370 to −807 containing three 
clustered STAT4 binding sites, the other nucleotides −800 
to −512 covering the single STAT4 site most proximal to 
the p66shc TSS (site A and B, respectively; Figure 2B). 
Figure 1: p66Shc alters the expression of several genes linked to the IL-12 pathway in B cells. A, B, D. qRT-PCR analysis 
of IFNγ, IL1B, IL10, IFNGR1, IL18RAP, IL7R and STAT4 mRNA in MEC-1 cells stably transfected with a construct encoding p66Shc 
(MEC-p66) or empty vector (MEC-Ctr). The relative abundance of gene transcripts was determined on triplicate samples from ≥3 
independent mRNA extractions using the ΔΔCt method and is expressed as normalized fold expression (mean±SD). C. Flow cytometric 
analysis of intracellular IFN-γ, IL-10 and IL-1β in MEC-Ctr and MEC-p66 cells treated for 24 h with a combination of PMA and A23187 
in the presence of brefeldin A. Data are expressed as mean fluorescence intensity (MFI) ± SD (n≥3). ***P≤0.001, **P≤0.01, *P≤0.05.
Table 1: List of IL-12 regulated genes found to be differentially up-regulated in p66Shc-overexpressing MEC-1 cells 
versus control 
Gene Symbol Gene name Fold-Change p-Value
IL10 Interleukin-10 12.7101 0.000006
IL18RAP Interleukin-18 Receptor Accessory Protein 4.3073 0.001364
IL1B Interleukin-1β 3.3917 0.001643
IL7R Interleukin 7 receptor α chain 2.8143 0.000170
IFNγ Interferon γ 2.5490 0.000992
IFNGR1 Interferon-γ Receptor α chain 2.0731 0.000330
Data obtained from the analysis of the Affymetrix HuGene-2.0-st-v1 arrays using Partek Genomics Suite version 6.6 
software.
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Figure 2: STAT4 regulates p66shc expression. A. In silico promoter analysis of the human p66shc promoter highlighting several 
putative STAT4 binding sites (grey shaded regions). SP1 binding sites identified in the analysis and known to be present in the p66shc 
promoter are shown in bold. The transcription start site (ATG) is also shown (underlined, italic). B. Top, schematic representation of the 
p66shc region taken into consideration for the ChIP experiments. Black arrows indicate the position of the primers used, dark squares the 
position of the STAT4 binding sites. The p66shc TSS is located in exon 2. Bottom, Nuclear extracts of EBV-B cells were subjected to ChIP 
assay with an antibody specific for STAT4. Precipitated DNA was amplified by qRT-PCR using primers described above. Unspecific IgG 
was used as control. Data are presented as percentage of input DNA (mean±SD; n=6). C. Scheme of the in vitro binding experiments. EBV-B 
nuclear extracts were used to pull down STAT4 bound to the biotinylated p66shc promoter, and bound STAT4 was detected by immunoblot. 
Lanes 1, 3 and 4 correspond to the beads bound to the promoter region containing one, three or all four STAT4 binding sites, respectively. 
Streptavidin beads incubated with nuclear extract were used as negative control (lane 0). Pull-down experiment using mutants of the 
putative STAT4 binding sites (M) showed no STAT4 immunoreactive band compared to the control (WT). (n=3). D-F. p66shc promoter 
activation assays in EBV-B cells. (D) Cells were co-transfected with reporter plasmids carrying p66shc promoter sequences containing 
none (pGL4p66Shc-460/+71), one (pGL4p66Shc-800/+71), or all (pGL4p66Shc-1300/+71) STAT4 binding sites, or empty vector (Ctr). A 
co-transfected Renilla plasmid was used as normalization control. (E) EBV-B cells were co-transfected with the pGL4p66Shc-1300/+71 
luciferase reporter, the Renilla transfection control and a plasmid encoding STAT4. (F) EBV-B cells were co-transfected with plasmids 
containing the mutated STAT4-binding sequences or the corresponding WT sequences, and the Renilla transfection control. ***P≤0.001; 
**P≤0.01, and *P≤0.05 (n=3)
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STAT4 binding was evaluated by ChIP assays using anti-
STAT4 IgG or control non-specific IgG followed by qRT-
PCR of the regions of interest, and normalized to the input 
(Figure 2B). A statistically significant binding of both 
site A and site B was observed when the ChIP assay was 
carried out using the anti-STAT4 antibody compared to the 
IgG control (Figure 2B).
STAT4 binding to the p66shc promoter was 
additionally confirmed using in vitro pull-down assays. 
The regions of interest, containing one, three or all the 
STAT4 binding sites, were amplified by PCR, using 
a 3’ modified primer to obtain a biotinylated p66shc 
promoter. The PCR products were bound to streptavidin 
beads and then incubated with nuclear cell extracts 
from EBV-B cells, then washed and subjected to SDS-
PAGE. The presence of STAT4 bound to the promoter 
fragments was detected using an anti-STAT4 antibody. 
An immunoreactive band, corresponding to STAT4, 
was present in the lanes containing the beads incubated 
with the PCR fragments, only a low background signal 
being detectable in the control sample incubated with 
streptavidin beads only (Figure 2C). No STAT4 was pulled 
down when biotinylated fragments containing one or all 
four STAT4 binding sites mutated were used, confirming 
that the putative STAT4 binding sites on the p66shc 
promoter are actually able to bind STAT4 (Figure 2C). 
Collectively, these results identify STAT4 as a novel 
transcription factor able to associate with the p66shc 
promoter.
STAT4 activates the p66shc promoter
To assess whether the presence of STAT4 binding 
sites influences the activity of the p66shc promoter in 
vitro EBV-B cells were transfected with luciferase reporter 
constructs containing fragments of the p66shc promoter 
differing in the number of STAT4 binding sites, i.e. none 
(pGL4p66Shc-460/+71), one (pGL4p66Shc-800/+71), 
or all four binding sites (pGL4p66Shc-1300/+71). The 
presence of one STAT4 site was sufficient to enhance 
p66shc promoter activity compared to the fragment 
with no STAT4 binding site, with a further increase in 
the presence of the pGL4p66Shc-1300/+71 construct, 
containing four STAT4 binding sites (Figure 2D). These 
data indicate that at least one accessible STAT4 binding 
site in the p66shc promoter is required to promote 
transcription.
EBV-B cells were next co-transfected with the 
pGL4p66Shc-1300/+71 reporter and a STAT4-encoding 
plasmid to verify whether increasing STAT4 levels 
would result in an enhancement in the p66shc promoter 
activity compared to the respective empty vector control. 
An increase in luciferase activity was observed in co-
transfected cells, indicating that STAT4 promotes p66shc 
transcription (Figure 2E). Of note, EBV-B cells tranfected 
with p66shc promoter constructs harboring point 
mutations in one or all the STAT4 binding sites displayed 
a significant reduction in the levels of luciferase activity 
compared to cells transfected with the WT reporters 
(Figure 2F). Moreover the activity of the mutated p66shc 
promoter was not enhanced in cells co-transfected with 
the STAT4 encoding construct (0.96±0.03 fold compared 
to cells trasfected with empty vector), at variance with the 
increase observed with the WT reporter (>2 fold, see also 
Figure 2E). Hence STAT4 binding to its recognition sites 
on the p66shc promoter is required for p66Shc expression 
(Figure 2F).
To evaluate the effect of STAT4 overexpression 
on endogenous p66Shc, EBV-B cells were transiently 
transfected with the STAT4-encoding plasmid and 
the levels of p66Shc were measured by qRT-PCR and 
immunoblot. p66Shc expression was increased both 
at the mRNA and protein level in cells overexpressing 
STAT4 compared to empty vector controls (Figure 
3A, 3B). As a complementary experiment, STAT4 was 
knocked down by transfecting EBV-B cells with specific 
esiRNA. A reduction in p66shc mRNA and protein was 
observed under these conditions, supporting the notion 
that STAT4 is required to promote p66shc transcription 
(Figure 3C, 3D).
IL-12 dependent STAT4 phosphorylation 
enhances p66shc promoter activity
Although STAT4 activity is regulated by IL-12-
dependent phosphorylation, our reporter gene experiments 
suggest that the overexpression of the transcription factor 
itself might be sufficient to activate the p66shc promoter 
independently of its phosphorylation, consistent with 
the finding that also unphosphorylated STATs are able 
to shuttle between cytoplasm and nucleus to activate 
transcription [26]. A role for STAT4 phosphorylation 
can however also be hypothesized, as EBV-B cells have 
been shown to produce IL-12 [27]. To evaluate whether 
phosphorylated STAT4 binds more efficiently the p66shc 
promoter, we performed ChIP experiments in EBV-B cells 
using anti-p-STAT4 IgG and control non-specific IgG. The 
results obtained using the anti-pSTAT4 IgG (Figure 4A) 
were comparable to those obtained using the anti-STAT4 
IgG (Figure 2B), suggesting that either STAT4 binds to its 
target sites with the same efficiency as the phosphorylated 
form or the STAT4 antibody is actually pulling down the 
phosphorylated form bound to the p66shc promoter.
To further address this issue and clarify the 
importance of IL-12 dependent STAT4 phosphorylation 
on the activity of the p66shc promoter, EBV-B cells were 
transfected with the p66Shc reporter construct carrying one 
STAT4 site (pGL4p66Shc-800/+71) and stimulated or not 
with IL-12 to promote STAT4 phosphorylation [28]. While 
significant levels of luciferase activity were observed 
in the absence of IL-12, these were enhanced in IL-12-
treated cells (Figure 4B), indicating that IL-12-dependent 
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STAT4 phosphorylation potentiates p66shc transcription 
in B cells. It is however noteworthy that IL-12 treatment 
not only induced STAT4 phosphorylation but also 
increased the basal levels of STAT4 mRNA and protein 
(Figure 4C, 4D).
To elucidate the contribution of STAT4 
phosphorylation to the IL-12-dependent increase in 
p66Shc expression we analyzed the response to IL-
12 of EBV-B cells pretreated with lisofylline (LSF), 
an inhibitor of STAT4 phosphorylation. LSF treatment 
resulted in a reduction in the levels of phosphorylated 
STAT4 without affecting the overall mRNA and protein 
levels (Figure 4C, 4D), which allows to specifically 
dissect the role of STAT4 phosphorylation. As shown in 
Figure 4C and 4D, the IL-12 dependent increase in p66Shc 
expression was largely abrogated in the presence of LSF. 
These results indicate that IL-12 treatment enhances 
p66shc transcription by increasing the levels of the 
activated form of its transcription factor STAT4.
Cell treatment with LSF alone resulted in a decrease 
in the basal levels of phosphorylated STAT4, however 
no changes in the mRNA and proteins levels of p66Shc 
were observed at the lower drug concentrations used 
(Supplementary Figure S3). In the presence of higher 
LSF concentrations, which affected more severely the 
basal levels of STAT4 phosphorylation, a decrease in 
p66Shc was detected, albeit not statistically significant. 
Nevertheless this was paralleled by a decrease in the p52/
Figure 3: STAT4 modulates the levels of p66Shc in B cells. A. qRT-PCR analysis of STAT4 and p66shc mRNA in EBV-B 
cells transiently transfected with either empty vector (Ctr) or an expression construct encoding STAT4 (STAT4). B. Immunoblot analysis 
of p46Shc, p52Shc and p66Shc 48 h after transfection with the STAT4-encoding construct in EBV-B cells. The histogram shows the 
quantification of the p66Shc immunoreactive band (n≥3). C. EBV-B cells were transfected with esiRNA targeting STAT4 and the levels of 
p66shc and STAT4 were measured by qRT-PCR. The relative abundance of the gene transcripts was determined on triplicate samples from 
at least 3 independent experiments using the ΔΔCt method and is expressed as the normalized fold expression (mean±SD). D. Immunoblot 
analysis of p46Shc, p52Shc and p66Shc 48 h after transfection of EBV-B cells with esiRNA targeting STAT4 (n≥3). Filters were reprobed 
for actin as loading control. The histogram shows the quantification of the p66Shc immunoreactive band. **P≤0.01; and *P≤0.05.
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Figure 4: Activation of STAT4 promotes p66Shc transcription and B-cell apoptosis. A. Nuclear extracts of EBV-B cells 
were subjected to ChIP assay with an antibody specific for p-STAT4. Precipitated DNA was amplified by qRT-PCR. Unspecific IgG was 
used as control. Data are presented as percentage of input DNA (mean±SD; n=6). B. Reporter gene assays on EBV-B cells co-transfected 
with the p66shc promoter reporter plasmid (pGL4p66Shc-460/+71) containing one STAT4 site and the control Renilla plasmid. Cells were 
stimulated or not with the IL-12 for 3 h prior to measuring luciferase activity (n>3). C. qRT-PCR analysis of p66shc and STAT4 mRNA in 
EBV-B cells as above in presence or absence of 20 μM LSF (n≥3). D. Immunoblot analysis of STAT4, pSTAT4 and the three Shc isoforms 
in EBV-B cells stimulated or not with IL-12 in presence or absence of 20 μM LSF. Filters were reprobed for actin as loading control. The 
histograms show the quantification of STAT4, p-STAT4 and p66Shc, normalized to actin (n=3). E. Flow cytometric analysis of AnnexinV+/
PI- EBV-B cells stimulated or not with IL-12 in presence or absence of 20 μM LSF followed by treatment with 500 ng/ml A23187. F. Flow 
cytometric analysis of AnnexinV+/PI- EBV-B cells transfected with siRNAs targeting p66shc or STAT4, respectively, and stimulated with 
IL-12/A23187. Cells transfected with a scrambled siRNA were used as control. Data represent the mean±SD of the Annexin V+/PI- cells 
(n=3). ***P≤ 0.001; **P≤0.01; and *P≤0.05.
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p46 Shc isoforms (Supplementary Figure S3B), suggesting 
a general and unspecific effect of LSF treatment at that 
concentration. Collectively, these results indicate that 
unphosphorylated STAT4 is sufficient to promote p66shc 
transcription but that this process is potentiated when 
STAT4 is phosphorylated in response to IL-12.
Once bound to its recognitions sites STAT4 is able 
to modulate gene transcription by recruiting not only 
other transcription factors but also chromatin-remodeling 
enzymes to promote active epigenetic marks such as 
trimethylation of lysine 4 of histone 3, leading to increased 
gene transcription, as shown for Th cells [29]. The fact 
that p66shc expression could be restored in cells that 
normally do not express it by treatment not only with 
DNA demethylating agents but also with inhibitors of 
histone deacetylases [8] suggests a role for the “histone 
code”, which may involve STAT4, in the regulation of 
p66shc transcription.
p66Shc promotes apoptosis in response to oxidative 
stress [4, 5, 7]. To investigate the role of STAT4 on the 
pro-apoptotic activity of p66Shc, EBV-B cells were 
stimulated with IL-12, alone or in combination with LSF, 
and then treated with the Ca2+ ionophore A23187, a potent 
inducer of apoptosis. Flow cytometric analysis revealed an 
increase in the number of Annexin V+/propidium iodide- 
cells following IL-12 stimulation, which was reversed by 
pre-treatment of the cells with LSF (Figure 4E). These 
results suggest, albeit indirectly, that activation of the 
IL-12 pathway leads to an increase in apoptosis as a result 
of the enhanced p66Shc expression observed under these 
conditions. To further test this hypothesis we measured 
the proportion of Annexin V+/propidium iodide- cells 
after transfection with siRNAs targeting p66shc or STAT4 
and stimulated with IL-12 and A23187. Interestingly, a 
reduction in the level of apoptotic cells was observed in 
EBV-B cells lacking STAT4, suggesting that STAT4 is 
required for IL-12/A23187 induced apoptosis. A similar 
reduction was observed in cells in which p66Shc was 
silenced, further supporting the importance of p66Shc in 
stress-induced apoptosis in B cells (Figure 4F).
p66Shc deficiency in CLL is associated with 
impaired STAT4 expression
We have previously reported that CLL B cells 
have a defect in p66shc expression that is not caused by 
methylation of the CpG dinucleotides in the gene promoter 
[6]. To understand whether STAT4 is involved in this 
defect, the relative abundance of the STAT4 transcript was 
measured in peripheral blood B cells from 30 CLL patients 
and 9 healthy controls. Patients were classified according 
to their mutational status of the Ig heavy chain variable 
(IGHV) region as mutated (M) or unmutated (UM), the 
latter being an unfavorable prognostic factor of disease 
progression and outcome [30]. CLL B cells showed a 
significant reduction in the levels of STAT4 mRNA, as 
assessed by qRT-PCR, compared with healthy controls, 
independently of the IGHV mutational status (Figure 
5A). STAT4 deficiency in CLL B cells was confirmed by 
immunoblot (Figure 5B), suggesting that the defect in 
p66shc expression in these patients might be accounted 
for, at least in part, by the low levels of STAT4. Consistent 
with the STAT4 defect, the mRNA levels of IFNγ, IL10 
and IL1β which are regulated by STAT4 [16, 19] were 
reduced in CLL compared to healthy B cells (Figure 5A).
A positive feedback loop couples p66Shc to 
STAT4 expression
The results of the gene array data showing that 
p66Shc overexpression leads to an increase in the levels 
of STAT4 in MEC-1 cells suggest the existence of a 
regulatory feedback loop between STAT4 and p66Shc 
which could account for the STAT4 defect observed 
in CLL B cells. To test this hypothesis positing that 
p66Shc, which relies on STAT4 for its expression, is 
in turn implicated in STAT4 expression, CLL B cells 
were transfected with a p66Shc-encoding construct and 
the levels of STAT4 were measured by qRT-PCR and 
immunoblot. As shown in Figure 5C, reconstitution of 
p66Shc expression in CLL cells resulted in a significant 
increase in the levels of STAT4 (Figure 5C). This result 
suggests that p66Shc might reciprocally regulate STAT4 
expression, accounting for the up-regulation of STAT4 
and its target genes in p66Shc overexpressing MEC-1 
cells (Figure 1A-1C). To further support this hypothesis 
we performed a complementary experiment transfecting 
EBV-B cells with a siRNA targeting the p66shc isoform 
and measured STAT4 by qRT-PCR and immunoblot. A 
reduction in the mRNA level of STAT4 was observed in B 
cells knocked down for p66Shc, which was paralleled by 
a significant reduction at the protein level (Figure 6A, 6B).
The pro-apoptotic function of p66Shc is correlated 
with its ability to promote ROS accumulation through 
two different molecular determinants, one mapping to 
S36 in the CH2 domain [7] and the second to residues 
EE132/133 in the cytochrome-c binding domain [31]. 
To assess whether the increase in STAT4 expression in 
p66Shc-overexpressing cells depends on its pro-oxidant 
activity we measured the levels of STAT4 in EBV-B cells 
transfected with vectors encoding either wild-type p66Shc 
(p66WT) or p66Shc mutants known to impact in its ROS-
generating activity, i.e. a S→A substitution at position 36 
(p66SA) [7] and E→Q substitutions at positions 132/133 
(p66QQ) [31]. p66SA or p66QQ expression resulted in an 
enhancement in the level of STAT4 comparable to the one 
observed in the presence of p66WT (Supplementary Figure 
S4), indicating that the positive regulatory mechanism 
linking p66Shc to STAT4 expression is independent of its 
pro-oxidant function.
In summary, we provide evidence of a mechanism 
responsible for p66Shc expression in B cells that is 
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independent of modifications of the gene promoter and 
involves the transcription factor STAT4, which is in 
turn regulated, at least in part, through a feedback loop 
involving p66Shc. Factors responsible for limiting this 
loop and molecular determinants of p66Shc involved 
in the regulation of STAT4 expression still remain to be 
determined.
By providing cytokines and chemokines, as well as 
low-affinity BCR ligands, that ensure self-renewal and 
extended lifespan to the leukemic cells [32], the stromal 
microenvironment of secondary lymphoid organs and 
bone marrow plays a major role in the extended survival 
of CLL B cells. Central to the success of these prosurvival 
strategies is an effective suppression of the T-cell response. 
CLL DCs are characterized by an abnormal pattern of 
cytokine production, which antagonizes the generation 
of cytotoxic effectors by favouring Th2 polarization 
and moreover suppress effector function through the 
production of IL-10 [33, 34]. CLL B cells also contribute 
to immunosuppression by anergizing T cells and evade 
killing by establishing dysfuctional immune synapses with 
CTLs [35]. Some of the immunomodulating cytokines 
produced by DC or effector T cells in CLL have also the 
ability to affect leukemic cells, as exemplified by IL-4, 
which promotes B cell survival [36]. Hence antibody-
based immunotherapies involving the combination of IL-
12 as adjuvant, which have been proposed as a strategy 
to correct the Th1/Th2 inbalance in CLL [37], require a 
Figure 5: Impaired STAT4 expression in primary CLL B cells. A. qRT-PCR analysis of p66shc, STAT4, IL10, IL1β and IFNγ 
mRNA in purified peripheral B cells from either healthy donors (Ctr, n=9) or CLL patients with mutated (M; n=15) or unmutated (U; n=15) 
IGHV. B. Representative immunoblot analysis of STAT4 in 2 healthy donors, 2 M-CLL and 2 U-CLL patients. The numbers below the 
representative blot refer to the quantification of STAT4 immunoreactive band in B-cell lysates from 10 M-CLL, 9 U-CLL and 6 healthy 
controls, of which at least 1 was included in each gel as reference. C. qRT-PCR analysis of STAT4 mRNA in CLL B cells nucleofected with 
either empty vector (CLL-Ctr) or an expression construct encoding p66Shc (CLL-p66). The relative abundance of STAT4 transcript was 
determined on triplicate samples from each patient using the ΔΔCt method and is expressed as the normalized fold expression (mean±SD; 
empty vector controls taken as 1 for all CLL samples). All samples (n=6) were checked for reconstitution of p66shc expression by qRT-
PCR (data not shown). A representative immunoblot of STAT4 and p66Shc is shown on the right. Filters were reprobed for actin as loading 
control. The histogram shows the quantification of STAT4 in B-cell lysates from 3 reconstituted CLL samples. ***P≤ 0.001; **P≤0.01; 
and *P≤0.05.
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thorough assessment of the potential pro-survival effects 
of this cytokine on the neoplastic cells. Our results provide 
the first evidence that STAT4, which is central for IL-
12R signaling, is expressed at abnormally low levels in 
CLL B cells. With this as a background we speculate that 
administration of IL-12 is highly likely to potentiate the 
antitumor T-cell response without unwanted prosurvival 
effects on the neoplastic cells, thus highlighting IL-12/
STAT4 pathway as a potential target for new therapeutic 
approaches in CLL.
MATERIALS AND METHODS
Cells, plasmids, transfections
MEC-1, EBV-B and human primary B cells were 
cultured in RPMI-1640 (Sigma-Aldrich, The Woodlands, 
TX) supplemented with 7.5% bovine calf serum at 37 °C 
in a humidified atmosphere with 5% CO2.
Plasmids included murine Stat4 pRc/CMV 
(Addgene, Cambridge, MA), pcDNA3.1 (Invitrogen, 
Carlsbad, CA) and the pcDNA3-p66Shc constructs 
encoding human wild-type p66Shc or the respective 
p66ShcSA (S→A substitution at position 36) and 
p66ShcQQ (EE3→QQ substitutions at positions 132-133) 
mutants [4].
The esiRNAs used to silence STAT4 (EHU069141) 
in human cells, as well as unrelated control RLUC esiRNA 
(EHURLUC) were purchased from Sigma-Aldrich. p66shc 
silencing in human cells was obtained using the p66Shc-1 
siRNA (GenScript Corporation, Piscataway, N.J).
Transfections were carried out using a modification 
of the DEAE-dextran procedure [38] or by electroporation. 
Assays were carried out after 24, 48 or 72 h.
Reconstitution of p66Shc expression in CLL B cells 
was obtained using the Human B-cell Nucleofector Kit 
(Amaxa Biosystems, Cologne, Germany) according to 
manufacturer’s instructions as previously described [12].
Patients and healthy donors
Blood samples were collected from 30 patients who 
satisfied standard morphologic and immunophenotypic 
criteria for CLL. All cases were obtained by the 
Hematology and Clinical Immunology Branch, Padua 
University School of Medicine (Padua, Italy). At the time 
of the collection, patients had never received treatment. 
Normal B cells from 9 buffy coats were used as controls 
for the healthy adult population. Informed consent was 
obtained from all patients.
B cells (CD19+) were purified by negative selection 
using the RosetteSep Human B-cell enrichment Cocktail 
(StemCell Technologies, Vancouver, BC), followed by 
density gradient centrifugation on Lympholite (Cedarlane 
Laboratories, Burlington, NC).
Cell treatments and Immunoblotting
EBV-B cells were incubated with 10, 20 or 40 μM 
LSF (Sigma-Aldrich) for 2, 4 or 16 h after which cells 
were collected and processed for quantitative RT-PCR 
or immunoblot analysis. Stimulation with IL-12 was 
performed following 2 h treatment of EBV-B cells with 20 
μM LSF using 2 ng/ml IL-12 (Immunotools, Friesoythe, 
Germany) for 1 or 2 h.
For immunoblot analyses, cells were lysed in 1% 
Triton X-100 in 20mM Tris-HCl (pH 8) and 150 mM 
NaCl (in the presence of a protease inhibitor cocktail, 
Figure 6: p66Shc affects STAT4 protein stability. A. qRT-PCR analysis of STAT4 and p66shc mRNA in EBV-B cells transfected 
with siRNA targeting p66shc. The relative abundance of the genes transcripts as described above and is expressed as the normalized fold 
expression (mean±SD, (n≥3). B. Immunoblot analysis of STAT4 and the three Shc isoforms in EBV-B cells transfected with a siRNA 
targeting p66shc. Filters were reprobed for actin as loading control. The histogram shows the quantification of the levels of STAT4, 
normalized to actin (n≥3). ***P≤0.001; and **P<0.01.
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Calbiochem, San Diego, CA). Immunoblot analysis was 
carried out by chemiluminescence (SuperSignal West Pico 
Chemiluminescent Substrate kit, Pierce, Waltham, MA) 
using as primary Abs anti-ShcA (Upstate Biotechnology, 
Lake Placid, NY), anti-STAT4 (Cell Signaling, Danvers, 
MA), anti p-STAT4 (Santa Cruz, Santa Cruz, CA), anti-
actin (Millipore, Billerica, MA) or anti-Lamin A/C (Cell 
Signaling) Abs and secondary peroxidase-labeled Abs 
(Amersham Pharmacia Biotech, Uppsala, Sweden).
RNA purification, gene expression profiling, and 
quantitative RT-PCR
Total RNA was extracted from MEC-Ctr and 
MEC-p66 cells, generated as previously described [12], 
using the RNeasy Micro Kit (Qiagen, Valencia, CA) and 
subjected to gene array profile analysis using Affymetrix 
HuGene-2_0-st-v1 arrays (carried out by the Microarray 
Unit at Cogentech, Milan, Italy).
Total RNA was extracted from B cells from healthy 
donors, CLL patients, MEC-1 or EBV-B cells using the 
RNeasy Plus Mini Kit (Qiagen) and retrotranscribed 
using the iScript™ cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA). Three independent reverse transcription 
reactions were performed on each sample. qRT-PCR was 
performed in triplicate on each cDNA on 96-well optical 
PCR plates (Sarstedt, Nümbrecht, Germany) using SSo 
Fast EvaGreenR SuperMix (Bio-Rad) and a CFX96 Real-
Time system (Bio-Rad). Results were processed and 
analyzed using CFX Manager Version 1.5 software (Bio-
Rad). Transcript levels were normalized to housekeeping 
controls. HPRT was used as housekeeping control for all 
qRT-PCR analyses with the exception of the experiments 
involving treatment with LSF, for which ACTB (β-actin) 
was used as this treatment resulted in alternations in HPRT 
mRNA levels. The primers used to amplify the cDNA 
fragments are listed in Supplementary Table S2.
Reporter gene assay
The human p66shc promoter fragments were 
generated by amplifying the p66shc promoter region 
from DNA extracted from EBV-B cells and ligated into 
the KpnI/EcoRV sites of the pGL4.17[luc2/Neo] basic 
vector (Promega, Madison, WI) using the primers listed 
in Supplementary Table S5. Mutagenesis of the STAT4 
binding sites was obtained by Polymerase Incomplete 
Primer Extension (PIPE) cloning method [40], using the 
primers listed in Supplemental Table S6.
For normalization of transfection efficiency, 
the pRL-TK plasmid that expresses Renilla luciferase 
(Promega) was used. The assays were carried out by 
transient transfection in EBV-B cells and the luciferase 
readings were recorded with a Promega Dual-Luciferase 
Assay System using a Junior LB 9509 Portable Tube 
Luminometer (Berthold, Harpenden, UK).
Chromatin immunoprecipitation and in vitro 
binding assay
ChIP assays for analysis of STAT4 occupancy 
on the p66shc promoter was carried out essentially as 
described by El-Osta and Wolfer [39]. Briefly, 20x106 
EBV-B cells were crosslinked with 0.8% formaldehyde 
for 10 min at room temperature. Cell nuclei were lysed 
and the lysate was sonicated 10 times for 10 sec to obtain 
average DNA fragment sizes of 500-1000 bases. After 
preclearing with 50 μl of protein-A-Sepharose (PAS) 
slurry (Amersham Pharmacia Biotech, Uppsala, Sweden), 
immunoprecipitations were carried out overnight using 5 
μg of anti-STAT4 or anti-p-STAT4 antibodies, or control 
IgG, followed by addition of 40 μl of PAS slurry for 2 
h to adsorb the protein-DNA complexes. Beads were 
washed eight-times, eluted in 400μl of buffer (50 mM Tris 
pH 8.0, 1 mM EDTA, 1% SDS, 50 mM NaHCO3), and 
crosslinking of protein-DNA complexes was reversed by 
heating at 65°C for 16 h. DNA was extracted with phenol/
chloroform and precipitated. The immunoprecipitated 
DNA fragments were quantitated by qRT-PCR as 
described above. The primer sets used for the analysis are 
listed in Supplementary Table S3.
For in vitro binding assays the p66shc promoter 
fragments were generated by PCR amplification of 
genomic DNA extracted from EBV-B cells using the 
PureLink Genomic DNA mini kit (Invitrogen). The 
primers used for amplification are listed in Supplementary 
Table S4. The mutated fragments were generated by PCR 
reactions using as templates the reporter plasmids with 
the mutated STAT4 binding sequences (see Reporter 
Gene Assay section). The PCR reactions were performed 
using the following amplification conditions: 95°C for 
3 minutes followed by 40 cycles at 95°C for 30 sec, 
60°C for 30 sec, 72°C for 45 sec, and a final elongation 
at 72°C for 4 min. PCR products were purified with the 
High Pure PCR Product Purification Kit (Roche Applied 
Science, Indianapolis, IN) and incubated for 2 h at room 
temperature with Pierce™ Streptavidin Magnetic Beads. 
Beads were then incubated overnight with EBV-B 
nuclear extracts, washed and subjected to SDS-PAGE 
and immunoblot using anti-STAT4 and anti-Lamin A/C 
antibodies.
Flow cytometry and apoptosis assay
Intracellular levels of IL-10, IFN-γ and IL-1β were 
quantitated on MEC-Ctr and MEC-p66 cells treated with a 
combination of 100 μg/ml phorbol 12-myristate 13-acetate 
and 500 ng/ml A23187 for 4 h, then added with 10 μM 
Brefeldin A and further incubated for 16 h. Cells were 
then fixed and permeabilized using the Cytofix/Cytoperm 
plus kit (BD Bioscience, San Jose, CA), stained with 
anti-human IL-10 (BioLegend, San Diego, CA), IFN-γ 
(eBioscience, San Diego, CA) or IL-1β (BioLegend) 
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Abs and analyzed using a Guava Easy Cyte (Millipore, 
Billerica, MA) flow cytometer.
For the apoptosis assays EBV-B cells were incubated 
with 20 μM LSF for 2 h before stimulation with 2 ng/
ml of IL-12 (Immunotools). After 1 h cells were treated 
with either DMSO or 500 ng/ml A23187 for 15 min at 
37°C to induce apoptosis. Apoptosis was measured by 
flow cytometric analysis of FITC-labeled Annexin-V+/PI− 
(e-Bioscience) stained cells.
Statistical analysis
Mean values, standard deviations and Student’s 
t-test (paired) were calculated using Microsoft Excel 
(Redmont, WA, USA). The one-way ANOVA with a 
Tukey's post hoc test was used for experiments in which 
multiple groups were compared and calculated using the 
GraphPad Software (La Jolla, CA, USA). A P≤0.05 was 
considered statistically significant.
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